This is a demo store. No orders will be fulfilled.

JI-101, 血管内皮生长因子受体 2 抑制剂

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
J647370-5mg
5mg 现货 Stock Image
J647370-10mg
10mg 现货 Stock Image
J647370-50mg
50mg 现货 Stock Image
J647370-100mg
100mg 现货 Stock Image

基本描述

别名 1-(1-((2-氨基吡啶-4-基)甲基]-1H-吲哚-4-基)-3-(5-溴-2-甲氧基苯基)脲
英文别名 Q27272064 | Urea, N-(1-((2-amino-4-pyridinyl)methyl)-1H-indol-4-yl)-N'-(5-bromo-2-methoxyphenyl)- | 1-(1-((2-AMINOPYRIDIN-4-YL)METHYL)-1H-INDOL-4-YL)-3-(5-BROMO-2-METHOXYPHENYL)UREA | SCHEMBL5585996 | 1-(1-((2-aminopyridin-4-yl)methyl)-1H-indol-4-yl)-3-(5
规格或纯度 Moligand™, ≥98%
英文名称 JI-101
生化机理 JI-101 是一种口服的血管内皮生长因子受体 2(VEGFR2)、表皮生长因子受体β(PDGFRβ)和 EphB4 多激酶抑制剂,具有很强的抗癌活性。
储存温度 -20°C储存
运输条件 超低温冰袋运输
作用类型 抑制剂
作用机制 血管内皮生长因子受体 2 抑制剂
产品介绍


JI-101 is an orally available multi-kinase inhibitor of VEGFR2 , PDGFRβ and EphB4 with potent anti-cancer activity.

In Vitro

JI-101 is found to be stable in all preclinical and human liver microsomes. The % metabolized is ranged between 3.03-3.95 across the tested species liver microsomes. The % metabolized is relatively higher in mice liver microsomes followed by dog, human and rat liver microsomes. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

JI-101excreted through bile along with its mono- and di-hydroxy metabolites. Following oral administration, JI-101 is rapidly absorbed, reaching C max within 2 h. The t 1/2 of JI-101 with intravenous and oral route is found to be 1.75±0.79 and 2.66±0.13 h, respectively. The Cl and Vd by intravenous route for JI-101 are found to be 13.0±2.62 mL/min/kg and 2.11±1.42 L/kg, respectively. The tissue distribution of JI-101 is extensive with rapid and preferred uptake into lung tissue. Overall, the oral bioavailability of JI-101 is 55% and the primary route of elimination for JI-101 is feces . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

IC50& Target:VEGFR2 PDGFRβ

纯度 ≥98%

产品属性

ALogP 3.4

名称和识别符

分子类型 小分子
IIUPAC Name 1-[1-[(2-aminopyridin-4-yl)methyl]indol-4-yl]-3-(5-bromo-2-methoxyphenyl)urea
INCHI 1S/C22H20BrN5O2/c1-30-20-6-5-15(23)12-18(20)27-22(29)26-17-3-2-4-19-16(17)8-10-28(19)13-14-7-9-25-21(24)11-14/h2-12H,13H2,1H3,(H2,24,25)(H2,26,27,29)
InChi Key ZXBFYBLSJMEBEP-UHFFFAOYSA-N
Smiles COC1=C(C=C(C=C1)Br)NC(=O)NC2=C3C=CN(C3=CC=C2)CC4=CC(=NC=C4)N
Isomeric SMILES COC1=C(C=C(C=C1)Br)NC(=O)NC2=C3C=CN(C3=CC=C2)CC4=CC(=NC=C4)N
关联CAS 900573-88-8
PubChem CID 11691242
MeSH Entry Terms 1-(1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl)-3-(5-bromo-2-methoxyphenyl)urea;JI 101;JI-101;JI101 cpd
分子量 466.3

化学和物理性质

溶解性 DMSO : ≥ 100 mg/mL (214.44 mM)
分子量 466.300 g/mol
XLogP3 3.400
氢键供体数Hydrogen Bond Donor Count 3
氢键受体数Hydrogen Bond Acceptor Count 4
可旋转键计数Rotatable Bond Count 5
精确质量Exact Mass 465.08 Da
单同位素质量Monoisotopic Mass 465.08 Da
拓扑极表面积Topological Polar Surface Area 94.200 Ų
重原子数Heavy Atom Count 30
形式电荷Formal Charge 0
复杂度Complexity 582.000
同位素原子数Isotope Atom Count 0
定义的原子立体中心计数Defined Atom Stereocenter Count 0
未定义的原子立体中心计数Undefined Atom Stereocenter Count 0
定义的键立体中心计数Defined Bond Stereocenter Count 0
未定义的键立体中心计数Undefined Bond Stereocenter Count 0
所有立体化学键的总数The total count of all stereochemical bonds 0
共价键合单元计数Covalently-Bonded Unit Count 1

安全和危险性(GHS)

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到8个结果

批号(Lot Number) 证书类型 货号
G2508472 分析证书 J647370
G2508496 分析证书 J647370
G2508497 分析证书 J647370
G2508500 分析证书 J647370
G2508470 分析证书 J647370
G2508471 分析证书 J647370
G2508498 分析证书 J647370
G2508499 分析证书 J647370

溶液计算器